Vanguard Investments Australia
RLAY icon

Vanguard Investments Australia’s Relay Therapeutics RLAY Stock Holding History

Vanguard Investments Australia’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$563K Hold
30,117
– – ﹤0.01% 1600
2026
Q1 		$300K Buy
+30,117
New +$269K ﹤0.01% 1844

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Vanguard Investments Australia's RLAY Position: Q2 2026 in Review

Vanguard Investments Australia held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 30,117 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Vanguard Investments Australia first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Vanguard Investments Australia held 30,117 shares of Relay Therapeutics worth $563K as of Q2 2026.
  • Vanguard Investments Australia left its Relay Therapeutics share count unchanged in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1600 holding.
  • Vanguard Investments Australia first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.